INCB054707, an oral Janus kinase (JAK)1 inhibitor, shows promise in the treatment of moderate-to-severe hidradenitis suppurativa, reducing the abscess and inflammatory nodule count in addition to having an acceptable safety profile, according to data from two phase II trials.
The search for chronic hand eczema relief has led to two different Janus kinase (JAK) inhibitors, one topical and the other oral, with both performing well in phase IIb trials reported during the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress.
Patients with moderate-to-severe atopic dermatitis (AD) see clinical improvements in all body locations when treated with 100- or 200-mg doses of oral abrocitinib as compared with placebo, reports a new posthoc analysis presented at the recently concluded 2020 Virtual Congress of the European Academy of Dermatology and Venereology (EADV 2020).
A new monoclonal antibody which targets interleukin-23 (IL-23) is now available in Malaysia. Guselkumab (TREMFYA™, Janssen Pharmaceutical Companies of Johnson & Johnson) is a subcutaneously injected agent that blocks the body’s inflammatory pathway, namely, IL-23.
Treatment with subcutaneous brodalumab is well tolerated in patients with hidradenitis suppurativa (HS), showing improvement in clinical outcomes and no serious adverse events, according to a recent study.
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
The use of epidermal growth factor receptor (EGFR) inhibitors for the treatment of nonsmall cell lung cancer (NSCLC) commonly triggers cutaneous side effects, which often leads to drug reductions or discontinuation, reports a new study at the recently concluded 2020 Virtual Congress of the European Academy of Dermatology and Venereology (EADV 2020).
Continuous treatment with baricitinib maintains clear or almost clear skin in patients with moderate-to-severe atopic dermatitis (AD) over 68 weeks, according to long-term results from the BREEZE-AD3 study presented during EADV 2020.
Topical application of passion fruit purple variant seeds extract shows potential in the treatment of acne vulgaris, producing improvements in lesion counts and ultraviolet‐induced red fluorescence with minimal adverse events and good satisfaction rate, according to the results of an open-label trial.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.